Atlas Trials

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

Clinical trial NCT05363111 · RECRUITING

Trial details

NCT number
NCT05363111
Sponsor
City of Hope Medical Center
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Start date
2022-11-22
Primary completion
2027-03-23
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.